 |
|
Pharmacoeconomic Considerations in Pharmaceutical Company Promotions
Gerald B. Rosenberg
Bayer Corporation West Haven, Conn
Arch Fam Med. 1995;4(8):674-675.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
On behalf of Bayer Corporation (formerly known as Miles Inc), I would like to make two points in response to the letter by Goldstein and Ives1 published in the December 1994 issue of the ARCHIVES.
First, independent data on pharmacy transactions from retail pharmacy computer systems across the country show that the 25% wholesale discount we offer on Adalat CC in comparison with Procardia XL is, in varying degrees depending on local pharmacist practice, passed on to consumers overall. Average monthly retail cost savings for a patient buying Adalat CC versus Procardia XL range, on average, from $8 at the 30-mg dose to $14 at the 60-mg dose to $16 at the 90-mg dose, which yield annual savings ranging from $77 to $2372 (Table).
Average wholesale price is used to calculate the cost comparison between Adalat CC and the other extendedrelease nifedipine
. . . [Full Text PDF of this Article]
|
